Summary:
This is a 15-week double blind, placebo-controlled, parallel-group, dose ranging, multi-center study was designed to evaluate the efficacy, safety, tolerability, and pharmaceokinetic of a orally administered study drug for patients with IBS-D.
Qualified Participants Must:
• Have had a colonoscopy performed within 5 years prior to screening
•
Be 18 to 65 years of age
•
Complete daily diary